MONJUVI 200 mg/5mL
Tafasitamab-cxix · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Incyte Corporation
MONJUVI is a injection, powder, lyophilized, for solution containing tafasitamab-cxix at 200 mg/5mL, taken intravenous. Manufactured by Incyte Corporation.
Key Facts
- Brand Name
- MONJUVI
- Generic Name
- Tafasitamab-cxix
- NDC Code (Product)
50881-013- Manufacturer
- Incyte Corporation
- Strength
- 200 mg/5mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761163
- Marketing Start
- 08/05/2020
Recall History
No Recall HistoryFrequently Asked Questions
What is MONJUVI used for?
MONJUVI contains Tafasitamab-cxix. It is a injection, powder, lyophilized, for solution taken intravenous. Consult your doctor for specific uses.
Is MONJUVI a controlled substance?
MONJUVI is not classified as a controlled substance by the DEA.
What is the generic name for MONJUVI?
The generic name for MONJUVI is Tafasitamab-cxix. There are no other listed brand versions of Tafasitamab-cxix.
What is the NDC code for MONJUVI 200 mg/5mL?
The NDC (National Drug Code) for MONJUVI 200 mg/5mL is 50881-013, listed by Incyte Corporation.
Other MONJUVI Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)